Literature DB >> 8346489

Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung.

M Hindle1, D A Newton, H Chrystyn.   

Abstract

BACKGROUND: A simple non-invasive method, in which a urine sample is taken 30 minutes after drug administration, has previously been shown to be a measure of the relative bioavailability of salbutamol to the lungs. This technique has been used to determine an optimal inhaler technique with commercially available metered dose inhalers (MDI).
METHODS: Ten healthy subjects were trained in the use of MDIs. Each inhaled 4 x 100 micrograms salbutamol in a series of experiments to examine the relative bioavailability to the lung after different respiratory manoeuvres. Urine collection intervals were 0-0.5 hours and 0.5-24 hours after administration.
RESULTS: There was significantly greater elimination of unchanged salbutamol 30 minutes after administration, indicating a greater relative bioavailability of salbutamol to the lungs after (1) exhaling gently to residual volume rather than to functional residual capacity before inhalation; (2) slow inhalation (10 l/min) compared with fast inhalation (50 l/min); (3) breath holding for 10 seconds after inhalation compared with no breath holding.
CONCLUSIONS: All patient information leaflets and healthcare personnel should standardise the instructions given to patients and should adopt the inhalation method proposed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8346489      PMCID: PMC464579          DOI: 10.1136/thx.48.6.607

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  Determination of the relative bioavailability of salbutamol to the lung following inhalation.

Authors:  M Hindle; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

2.  Use of pressurised aerosols by asthmatic patients.

Authors:  I C Paterson; G K Crompton
Journal:  Br Med J       Date:  1976-01-10

3.  Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; T A Moreland; A D Struthers; G A Clark; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Effect of depth of inhalation on aerosol persistence during breath holding.

Authors:  E D Palmes; C S Wang; R M Goldring; B Altshuler
Journal:  J Appl Physiol       Date:  1973-03       Impact factor: 3.531

Review 5.  How should a pressurized beta-adrenergic bronchodilator be inhaled?

Authors:  S P Newman; D Pavia; S W Clarke
Journal:  Eur J Respir Dis       Date:  1981-02

6.  The fate of inhaled terbutaline.

Authors:  D S Davies
Journal:  Eur J Respir Dis Suppl       Date:  1984

7.  Aerosol inhalation and depth of deposition in the human lung. The effect of airway obstruction and tidal volume inhaled.

Authors:  D Pavia; M Thomson; H S Shannon
Journal:  Arch Environ Health       Date:  1977 May-Jun

8.  A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline.

Authors:  L Borgström; M Nilsson
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

9.  Deposition of pressurised aerosols in the human respiratory tract.

Authors:  S P Newman; D Pavia; F Morén; N F Sheahan; S W Clarke
Journal:  Thorax       Date:  1981-01       Impact factor: 9.139

10.  Effects of various inhalation modes on the deposition of radioactive pressurized aerosols.

Authors:  S P Newman; D Pavia; N Garland; S W Clarke
Journal:  Eur J Respir Dis Suppl       Date:  1982
  10 in total
  23 in total

1.  Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion.

Authors:  O A Aswania; S A Corlett; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

2.  Lung distribution of inhaled drugs.

Authors:  S P Newman
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

3.  In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler.

Authors:  Peter H Hirst; Gary R Pitcairn; Jeff G Weers; Thomas E Tarara; Andrew R Clark; Luis A Dellamary; Gail Hall; Jolene Shorr; Stephen P Newman
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

Review 4.  Methods to identify drug deposition in the lungs following inhalation.

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

5.  Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.

Authors:  Heather S Tomlinson; Sarah A Corlett; Martin B Allen; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

6.  Generic salbutamol metered dose inhalers.

Authors:  J P Watson; R A Lewis
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

7.  Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence.

Authors:  P Zanen; J W Lammers
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 8.  Studies using radiolabelled aerosols in children.

Authors:  M L Everard
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

Review 9.  Standards for bioequivalence of inhaled products.

Authors:  H Chrystyn
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

10.  Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices.

Authors:  M Hindle; H Chrystyn
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.